We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$206M
Cap. Flow
+$79.9M
Cap. Flow %
10.7%
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16

Top Buys

1
ALKS icon
Alkermes
ALKS
+$15.6M
2
STAA icon
STAAR Surgical
STAA
+$15.2M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.8M
4
LNTH icon
Lantheus
LNTH
+$12.5M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$11.4M

Top Sells

1
AGN
Allergan plc
AGN
+$16.2M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.6M
3
NVRO
NEVRO CORP.
NVRO
+$12.9M
4
WMGI
Wright Medical Group Inc
WMGI
+$12.8M
5
ABBV icon
AbbVie
ABBV
+$11.7M

Sector Composition

1 Healthcare 46.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$142M 18.96%
440,000
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$133M 17.75%
+800,000
New +$126M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$33.3M 4.46%
350,000
-350,000
-50% -$30.3M
BHVN
4
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32.7M 4.37%
600,000
+100,000
+20% +$4.95M
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$27.2M 3.64%
4,300,066
– –
VRAY
6
DELISTED
ViewRay, Inc.
VRAY
$23.5M 3.15%
5,574,366
+2,573,005
+86% +$8.32M
AMRN
7
Amarin Corp
AMRN
$293M
$22.5M 3.01%
52,462
-25,989
-33% -$9.87M
BHVN
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$22.3M 2.98%
409,338
-123,253
-23% -$6.1M
ALKS icon
9
Alkermes
ALKS
$8.79B
$21.1M 2.82%
1,033,500
+784,500
+315% +$15.6M
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19M 2.54%
49,855
+34,519
+225% +$11.4M
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$18.4M 2.47%
41,212
-4,367
-10% -$1.55M
STAA icon
12
STAAR Surgical
STAA
$1.32B
$16.3M 2.18%
+462,118
New +$15.2M
XENT
13
DELISTED
Intersect ENT, Inc
XENT
$15.7M 2.1%
631,023
-148,111
-19% -$3M
PGNX
14
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$15.6M 2.09%
3,060,923
+1,476,998
+93% +$7.81M
NSTG
15
DELISTED
NanoString Technologies, Inc.
NSTG
$15.5M 2.07%
555,600
+444,800
+401% +$10.8M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.23B
$14.8M 1.98%
533,301
-597,800
-53% -$13.6M
DERM
17
DELISTED
Dermira, Inc.
DERM
$13.6M 1.82%
896,334
+316,734
+55% +$2.73M
SCTL
18
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$13.2M 1.77%
721,073
-380,279
-35% -$5.46M
LNTH icon
19
Lantheus
LNTH
$7B
$12.7M 1.7%
+617,953
New +$12.5M
VAPO
20
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$12.2M 1.63%
+125,387
New +$10.6M
SIEN
21
DELISTED
Sientra, Inc.
SIEN
$11.5M 1.54%
128,699
-71,491
-36% -$5.39M
VCEL icon
22
Vericel Corp
VCEL
$2.38B
$10.8M 1.44%
620,199
+383,149
+162% +$6.52M
LJPC
23
DELISTED
La Jolla Pharmaceutical Company
LJPC
$10.6M 1.41%
2,688,068
+2,506,224
+1,378% +$14.8M
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
$8.99M 1.2%
+83,100
New +$8.89M
SLGL icon
25
Sol-Gel Technologies
SLGL
$274M
$8.95M 1.2%
52,182
-4,148
-7% -$358K
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Broadfin Capital deployed $79.9M of net new capital in Q4 2019, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 54% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $13.6M trimmed.

  • Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
  • Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
  • Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
  • Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
  • Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
  • Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
  • Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.